Cenna Biosciences secures $2.7M Phase II SBIR grant for Alzheimer's peptide drug, Nubytide™.

Cenna Biosciences, a biopharmaceutical company based in La Jolla, has secured a $2.7 million Phase II SBIR grant from the NIH and NIA to advance its peptide drug, Nubytide™, aimed at preventing and treating Alzheimer’s disease. This innovative therapy promises easier administration and potentially fewer side effects compared to current monoclonal antibody treatments. An IND filing is expected in early 2025, with plans for further investment to expedite development.

September 23, 2024
5 Articles